# US 2023/0390322 A1 · High concentration methylcobalamin or combination of methyl- and hydroxy-cobalamin for the treatment of cobalamin c deficiency disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390322 A1
- Document ID: US20230390322A1
- Status: Published application
- Kind: A1
- Application number: 18/032,132
- Filed: 2021-10-12
- Published: 2023-12-07
- Earliest claimed: 2020-10-16
- Assignees: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Applicants: THE U.S.A., as represented by the Secretary, Department of Health and Human Services
- Inventors: Charles P. Venditti; Jennifer Lyn Sloan; Eirini Manoli
- Web page: https://patentgrep.com/patent/US20230390322A1

## CPC

- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods are disclosed for treating a subject with a cobalamin C (cblC) deficiency. These methods include selecting a human subject with the cblC deficiency; and administering about 5 mg to about 10 grams of methylcobalamin (MeCbl) daily to the human subject. Methods also are disclosed for treating a fetus with a cobalamin C (cblC) deficiency. The methods include selecting a female human subject pregnant with the fetus that has the cblC deficiency; and administering about 5 mg to about 10 grams of MeCbl daily to the female human subject, in order to treat the cblC deficiency in the fetus. Optionally, OHCbl can be administered to the subject.

## Claims

### Claim 1

A method of treating a subject with a cobalamin C (cblC) deficiency, comprising:
selecting a human subject with the cblC deficiency; and
administering about 5 mg to about 10 grams of methylcobalamin (MeCbl) daily to the human subject, thereby treating the cblC deficiency in the subject.

### Claim 2 (depends on 1)

The method of claim 1, comprising administering about 10 mg to about 10 grams of MeCbl daily to the human subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the human subject is an infant.

### Claim 4 (depends on 1)

The method of claim 1, wherein the human subject is a child.

### Claim 5 (depends on 1)

The method of claim 1, wherein the human subject is an adult.

### Claim 6 (depends on 1)

The method of claim 1, wherein the human subject has macular disease or a retinal degeneration, and wherein retinal function is improved in the human subject following the administering.

### Claim 7 (depends on 1)

The method of claim 1, wherein the human subject has impaired neurocognitive function, and wherein a neurocognitive outcome is improved in the human subject following the administering.

### Claim 8 (depends on 1)

The method of claim 1, wherein the human subject has seizures, and wherein seizures are improved in the human subject following the administering.

### Claim 9 (depends on 1)

The method of claim 1, wherein the human subject has neuropathy, and wherein neuropathy is improved in the human subject following the administering.

### Claim 10 (depends on 1)

The method of claim 1, wherein the human subject has homocystinuria/hyperhomocysteinemia.

### Claim 11 (depends on 10)

The method of claim 10, wherein the human subject has methylmalonic acidemia.

### Claim 12

A method of treating a fetus with a cblC deficiency, comprising:
selecting a female human subject pregnant with the fetus that has the cblC deficiency; and
administering about 5 mg to about 10 grams of MeCbl daily to the female human subject, thereby treating the cblC deficiency in the fetus.

### Claim 13 (depends on 12)

The method of claim 12, wherein the female human subject is in the second or third trimester.

### Claim 14 (depends on 13)

The method of claim 13, wherein the fetus has intrauterine growth retardation (IUGR), and wherein growth of the fetus is improved following administration to the human subject.

### Claim 15 (depends on 12)

The method of claim 12, wherein one or more of ocular function, macular function, cardiac function, kidney function, brain growth, neurocognitive function or hydrocephalus is improved in the fetus following birth as compared to a control.

### Claim 16 (depends on 15)

The method of claim 15, wherein the control is the ocular function, macular function, cardiac function, kidney function, brain growth, neurocognitive function or hydrocephalus in a fetus following birth, wherein the fetus was not administered the MeCbl.

### Claim 17 (depends on 1)

The method of claim 1, wherein the MeCbl is administered to the human subject at a dose of about 0.05 to about 100 mg/kg/day.

### Claim 18 (depends on 17)

The method of claim 17, wherein the MeCbl is administered to the human subject at a dose of about 0.3 to about 50 mg/kg/day

### Claim 19 (depends on 1)

The method of claim 1, further comprising administering to the human subject a therapeutically effective amount of hydroxocobalamin (OHCbl).

### Claim 20 (depends on 19)

The method of claim 19, comprising administering about 5 mg to about 50 mg of OHCbl.

### Claim 21 (depends on 20)

The method of claim 20, comprising administering to the human subject about 5 mg to about 50 mg of MeCbl and about 5 mg to about 10 grams of OHCbl as a single dose to the human subject.

### Claim 22 (depends on 1)

The method of claim 1, wherein the MeCbl is administered intravenously, intramuscularly, or subcutaneously.

### Claim 23 (depends on 1)

The method of claim 1, further comprising performing an assay on a biological sample from the subject, wherein the assay is
a) urine organic acid analysis
b) serum methylmalonic acid analysis;
c) total plasma homocysteine analysis;
d) plasma amino acid analysis;
e) serum vitamin B12 level;
f) plasma acylcarnitine analysis; or
g) measurement of cystathionine.

### Claim 24 (depends on 1)

The method of claim 1, wherein the human subject has a cblC, epicblC, cblD-combined, cblD-homocystinuria, cblE, cblF, cblG, cblJ or cblX disorder.

### Claim 25 (depends on 1)

The method of claim 1, further comprising administering to the subject an effective amount of betaine, folate and/or folinic acid.

### Claim at position 26

26-39. (canceled)
